Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belantamab + belantamab mafodotin
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This entry refers to a **combination of belantamab and belantamab mafodotin**. **Belantamab mafodotin** is an **antibody-drug conjugate (ADC)** consisting of a **humanized IgG1κ monoclonal antibody targeting B-cell maturation antigen (BCMA)**, conjugated via a stable, protease-resistant linker to the cytotoxic agent **monomethyl auristatin-F (MMAF)**. The drug acts by binding to BCMA on malignant plasma cells, delivering MMAF inside the cell, leading to **microtubule disruption, cell cycle arrest, and apoptosis**. It also induces immune-mediated cytotoxicity (antibody-dependent cellular cytotoxicity and phagocytosis), enhancing anti-tumor effect[1][3][5][7]. Belantamab (without the mafodotin) as a singular entity has not been marketed separately; activity and approvals relate specifically to the mafodotin-conjugate. Belantamab mafodotin has been approved for treatment of **relapsed or refractory multiple myeloma** in patients who have received at least four prior therapies, but this approval has been voluntarily withdrawn in the US following confirmatory trial failure[1][2][3][5].
- Other names
- belantamab mafodotin-blmf
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on belantamab + belantamab mafodotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belantamab + belantamab mafodotin.